Data from four new studies examining safety and efficacy of desvenlafaxine succinate, a serotonin-norepinephrine reuptake inhibitor being studied as a potential treatment for adults with major depressive disorder , were presented today at the 2007 American Psychiatric Association annual meeting in San Diego, Calif., by Wyeth Pharmaceuticals, a division of Wyeth .
From: biz.yahoo.com
New Study Results Provide Additional Data about Short- and Long-Term Use of Desvenlafaxine Succinate in the Treatment ...
Posted by Ruslan Abuzant at 6:19 PM
Subscribe to:
Post Comments (Atom)
0 comments:
Post a Comment